albendazole has been researched along with Parasitemia in 22 studies
Parasitemia: The presence of parasites (especially malarial parasites) in the blood. (Dorland, 27th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| " We evaluated the effects of albendazole treatment, every three months for 21 months, on STH, malarial parasitemia and allergy." | 9.17 | The effect of three-monthly albendazole treatment on malarial parasitemia and allergy: a household-based cluster-randomized, double-blind, placebo-controlled trial. ( Ariawan, I; Brice, GT; de Craen, AJ; Djuardi, Y; Hamid, F; Houwing-Duistermaat, JJ; Kaisar, MM; Lell, B; Luty, AJ; May, L; Prasetyani, MA; Sartono, E; Sauerwein, R; Supali, T; Sutanto, I; Tsonaka, R; van Lieshout, L; van Ree, R; Verweij, JJ; Wahyuni, S; Wammes, LJ; Wibowo, H; Wiria, AE; Yazdanbakhsh, M, 2013) |
| "Repeated, single, oral doses of combinations of ivermectin, diethylcarbamazine (DEC) or albendazole are recognized as important tools for parasite control in lymphatic filariasis." | 9.09 | Two-year follow-up of the microfilaraemia of asymptomatic brugian filariasis, after treatment with two, annual, single doses of ivermectin, diethylcarbamazine and albendazole, in various combinations. ( Babu, BS; John, A; Kumaraswami, V; Shenoy, RK; Suma, TK, 2000) |
| "In Africa, albendazole and ivermectin are currently used in combination for annual mass drug administration (MDA) for lymphatic filariasis (LF) elimination." | 5.20 | Randomised controlled clinical trial of increased dose and frequency of albendazole and ivermectin on Wuchereria bancrofti microfilarial clearance in northern Malawi. ( Banda, LG; French, N; Horton, J; Koole, O; Ngwira, BM; Phiri, AJ; Piston, WN; Taegtmeyer, M; Tafatatha, TT; Wilson, TP, 2015) |
| " We evaluated the effects of albendazole treatment, every three months for 21 months, on STH, malarial parasitemia and allergy." | 5.17 | The effect of three-monthly albendazole treatment on malarial parasitemia and allergy: a household-based cluster-randomized, double-blind, placebo-controlled trial. ( Ariawan, I; Brice, GT; de Craen, AJ; Djuardi, Y; Hamid, F; Houwing-Duistermaat, JJ; Kaisar, MM; Lell, B; Luty, AJ; May, L; Prasetyani, MA; Sartono, E; Sauerwein, R; Supali, T; Sutanto, I; Tsonaka, R; van Lieshout, L; van Ree, R; Verweij, JJ; Wahyuni, S; Wammes, LJ; Wibowo, H; Wiria, AE; Yazdanbakhsh, M, 2013) |
| " A trial was therefore conducted to evaluate whether a course of albendazole would bring about a slower decrease in the Loa microfilaraemia, and thus could be used as a mass 'clearing' treatment, before the distribution of ivermectin in areas where onchocerciasis and loiasis are co-endemic." | 5.10 | Effects of a 3-day regimen of albendazole (800 mg daily) on Loa loa microfilaraemia. ( Boussinesq, M; Kamgno, J; Moyou-Somo, R; Pion, SD; Tsague-Dongmo, L, 2002) |
| "Repeated, single, oral doses of combinations of ivermectin, diethylcarbamazine (DEC) or albendazole are recognized as important tools for parasite control in lymphatic filariasis." | 5.09 | Two-year follow-up of the microfilaraemia of asymptomatic brugian filariasis, after treatment with two, annual, single doses of ivermectin, diethylcarbamazine and albendazole, in various combinations. ( Babu, BS; John, A; Kumaraswami, V; Shenoy, RK; Suma, TK, 2000) |
| " Adults were randomized into 2 treatment arms, DEC 6 mg/kg + ALB 400 mg (N = 12) or DEC 6 mg/kg + ALB 400 mg + IVM 200 μg/kg (N = 12), and monitored for microfilaria, parasite antigenemia, adverse events (AEs), and serum drug levels." | 2.82 | Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis. ( Baea, M; Fleckenstein, LL; Kazura, JW; King, CL; Lombore, B; Maki, E; Sanuku, N; Satofan, S; Schmidt, MS; Siba, PM; Thomsen, EK; Weil, GJ, 2016) |
| "These findings suggest that increasing the dosage and frequency of albendazole-ivermectin treatment enhances suppression of microfilariae but that this effect may not be attributable to improved adulticidal activity." | 2.75 | Use of high-dose, twice-yearly albendazole and ivermectin to suppress Wuchereria bancrofti microfilarial levels. ( Coulibaly, ME; Coulibaly, SY; Coulibaly, YI; Dembele, B; Diallo, AA; Diaman Keita, A; Dolo, H; Doumbia, SS; Fay, MP; Klion, AD; Konate, S; Nutman, TB; Sanogo, D; Soumaoro, L; Traore, SF, 2010) |
| "Treatment with albendazole led to a significant reduction in IgG3 levels against both GMZ2 and GLURP R0." | 1.62 | Effect of hookworm infection and anthelmintic treatment on naturally acquired antibody responses against the GMZ2 malaria vaccine candidate and constituent antigens. ( Abu, EK; Adu, B; Ahenkorah, B; Amoani, B; Barnes, P; Cappello, M; Dwomoh, D; Gyan, B; Nuvor, SV; Sakyi, SA; Sarkodie-Addo, T; Sewor, C; Theisen, M; Wilson, MD, 2021) |
| "Lymphatic filariasis is widely endemic in Myanmar." | 1.48 | The prevalence of lymphatic filariasis infection and disease following six rounds of mass drug administration in Mandalay Region, Myanmar. ( Aye, NN; Bradbury, RS; Dickson, BFR; Douglass, J; Graves, PM; McBride, WJ; Nwe, TW; Shwe, M; Wai, T; Win, SS, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (9.09) | 18.2507 |
| 2000's | 6 (27.27) | 29.6817 |
| 2010's | 13 (59.09) | 24.3611 |
| 2020's | 1 (4.55) | 2.80 |
| Authors | Studies |
|---|---|
| Cross, RM | 1 |
| Flanigan, DL | 1 |
| Monastyrskyi, A | 1 |
| LaCrue, AN | 1 |
| Sáenz, FE | 1 |
| Maignan, JR | 1 |
| Mutka, TS | 1 |
| White, KL | 1 |
| Shackleford, DM | 1 |
| Bathurst, I | 1 |
| Fronczek, FR | 1 |
| Wojtas, L | 1 |
| Guida, WC | 1 |
| Charman, SA | 1 |
| Burrows, JN | 1 |
| Kyle, DE | 1 |
| Manetsch, R | 1 |
| Amoani, B | 1 |
| Gyan, B | 1 |
| Sakyi, SA | 1 |
| Abu, EK | 1 |
| Nuvor, SV | 1 |
| Barnes, P | 1 |
| Sarkodie-Addo, T | 1 |
| Ahenkorah, B | 1 |
| Sewor, C | 1 |
| Dwomoh, D | 1 |
| Theisen, M | 1 |
| Cappello, M | 1 |
| Wilson, MD | 1 |
| Adu, B | 1 |
| Dickson, BFR | 1 |
| Graves, PM | 1 |
| Aye, NN | 1 |
| Nwe, TW | 1 |
| Wai, T | 1 |
| Win, SS | 1 |
| Shwe, M | 1 |
| Douglass, J | 1 |
| Bradbury, RS | 1 |
| McBride, WJ | 1 |
| Wiria, AE | 1 |
| Hamid, F | 1 |
| Wammes, LJ | 1 |
| Kaisar, MM | 1 |
| May, L | 1 |
| Prasetyani, MA | 1 |
| Wahyuni, S | 1 |
| Djuardi, Y | 1 |
| Ariawan, I | 1 |
| Wibowo, H | 1 |
| Lell, B | 1 |
| Sauerwein, R | 1 |
| Brice, GT | 1 |
| Sutanto, I | 1 |
| van Lieshout, L | 1 |
| de Craen, AJ | 1 |
| van Ree, R | 1 |
| Verweij, JJ | 1 |
| Tsonaka, R | 1 |
| Houwing-Duistermaat, JJ | 1 |
| Luty, AJ | 1 |
| Sartono, E | 1 |
| Supali, T | 1 |
| Yazdanbakhsh, M | 1 |
| Dorkenoo, AM | 1 |
| Sodahlon, YK | 1 |
| Bronzan, RN | 1 |
| Yakpa, K | 1 |
| Sossou, E | 1 |
| Ouro-Medeli, A | 1 |
| Teko, M | 1 |
| Seim, A | 1 |
| Mathieu, E | 1 |
| Tafatatha, TT | 1 |
| Ngwira, BM | 1 |
| Taegtmeyer, M | 1 |
| Phiri, AJ | 1 |
| Wilson, TP | 1 |
| Banda, LG | 1 |
| Piston, WN | 1 |
| Koole, O | 1 |
| Horton, J | 1 |
| French, N | 1 |
| Mouhari-Toure, A | 1 |
| N'Timon, B | 1 |
| Kumako, V | 1 |
| Darre, T | 1 |
| Saka, B | 1 |
| Tchaou, M | 1 |
| Amegbor, K | 1 |
| Kombate, K | 1 |
| Balogou, AA | 1 |
| Pitche, P | 1 |
| Kepha, S | 1 |
| Nuwaha, F | 1 |
| Nikolay, B | 1 |
| Gichuki, P | 1 |
| Mwandawiro, CS | 1 |
| Mwinzi, PN | 1 |
| Odiere, MR | 1 |
| Edwards, T | 1 |
| Allen, E | 1 |
| Brooker, SJ | 1 |
| Thomsen, EK | 1 |
| Sanuku, N | 1 |
| Baea, M | 1 |
| Satofan, S | 1 |
| Maki, E | 1 |
| Lombore, B | 1 |
| Schmidt, MS | 1 |
| Siba, PM | 1 |
| Weil, GJ | 1 |
| Kazura, JW | 2 |
| Fleckenstein, LL | 1 |
| King, CL | 1 |
| Koumar, Y | 1 |
| Lechiche, C | 1 |
| Sotto, A | 1 |
| Lachaud, L | 1 |
| Moliner, JV | 1 |
| Valverde, AG | 1 |
| Sorolla, JM | 1 |
| Dembele, B | 1 |
| Coulibaly, YI | 1 |
| Dolo, H | 1 |
| Konate, S | 1 |
| Coulibaly, SY | 1 |
| Sanogo, D | 1 |
| Soumaoro, L | 1 |
| Coulibaly, ME | 1 |
| Doumbia, SS | 1 |
| Diallo, AA | 1 |
| Traore, SF | 1 |
| Diaman Keita, A | 1 |
| Fay, MP | 1 |
| Nutman, TB | 1 |
| Klion, AD | 1 |
| Akkari, H | 1 |
| Gharbi, M | 1 |
| Darghouth, MA | 1 |
| Tsague-Dongmo, L | 1 |
| Kamgno, J | 2 |
| Pion, SD | 1 |
| Moyou-Somo, R | 1 |
| Boussinesq, M | 2 |
| Scheuring, UJ | 1 |
| Seitz, HM | 1 |
| Wellmann, A | 1 |
| Hartlapp, JH | 1 |
| Tappe, D | 1 |
| Brehm, K | 1 |
| Spengler, U | 1 |
| Sauerbruch, T | 1 |
| Rockstroh, JK | 1 |
| Sahoo, PK | 1 |
| Satapathy, AK | 1 |
| Michael, E | 1 |
| Ravindran, B | 1 |
| Franco-Alvarez de Luna, F | 1 |
| Giménez-Almenara, G | 1 |
| Vidal, E | 1 |
| Casal, M | 1 |
| Addiss, DG | 1 |
| Beach, MJ | 1 |
| Streit, TG | 1 |
| Lutwick, S | 1 |
| LeConte, FH | 1 |
| Lafontant, JG | 1 |
| Hightower, AW | 1 |
| Lammie, PJ | 1 |
| Shenoy, RK | 2 |
| Dalia, S | 1 |
| John, A | 2 |
| Suma, TK | 2 |
| Kumaraswami, V | 2 |
| Babu, BS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy of Higher Albendazole and Ivermectin Doses on Wuchereria Bancrofti Microfilarial Clearance in Malawi, Open Label Study[NCT01213576] | 70 participants (Actual) | Interventional | 2009-01-31 | Terminated (stopped due to Introduction of National Mass Drug Administration Campaign and failure to identify appropriate participants.) | |||
| Impact of Repeated Anthelminthic Treatment on Malaria in School Children: an Individual Randomized, Double-blind, Placebo-controlled Trial in Western Kenya[NCT01658774] | 2,377 participants (Actual) | Interventional | 2013-01-31 | Completed | |||
| Safety and Efficacy of Combination Therapy With Ivermectin, Diethylcarbamazine, and Albendazole (IDA) for Individuals With Onchocerciasis[NCT04188301] | Phase 2 | 154 participants (Actual) | Interventional | 2019-12-06 | Completed | ||
| Evaluate Triple-Drug Therapy With Diethylcarbamize (DEC), Albendazole (ALB) and Ivermectin (IVM) That Could Accelerate LF Elimination Outside of Africa[NCT01975441] | Phase 2 | 182 participants (Actual) | Interventional | 2014-05-31 | Completed | ||
| Community Based Safety Study of 2-drug (Diethylcarbamazine and Albendazole) Versus 3-drug (Ivermectin, Diethylcarbamazine and Albendazole) Therapy for Lymphatic Filariasis[NCT02899936] | 23,789 participants (Actual) | Interventional | 2016-07-31 | Completed | |||
| Safety and Efficacy of Novel Combination Regimens for Treatment of Onchocerciasis[NCT06070116] | Phase 2 | 300 participants (Anticipated) | Interventional | 2024-01-15 | Not yet recruiting | ||
| Microfilarial Clearance From the Eye and Ocular Changes Associated With Ivermectin Treatment in Individuals With Onchocerciasis[NCT03517462] | 231 participants (Actual) | Interventional | 2018-08-06 | Completed | |||
| A Clinical Trial to Assess the Safety and Efficacy of Moxidectin Combination Treatments vs. Ivermectin Combination Treatments for Bancroftian Filariasis[NCT04410406] | Phase 3 | 164 participants (Actual) | Interventional | 2020-08-20 | Active, not recruiting | ||
| Community Studies to Monitor the Impact of Triple Drug Therapy Relative to Double Drug Therapy on Lymphatic Filariasis Infection Indicators[NCT03352206] | 20,092 participants (Actual) | Observational | 2017-10-18 | Completed | |||
| Effect of Albendazole and Ivermectin Dose on Wuchereria Bancrofti Microfilarial Clearance in Mali: A Randomized, Open Label Study[NCT00339417] | Phase 2 | 1,000 participants (Anticipated) | Interventional | 2006-02-22 | Completed | ||
| Treatment of Mansonella Perstans Infection in an Area Coendemic for Lymphatic Filariasis: A Pilot Study of the Effects of Doxycycline[NCT00340691] | Phase 2 | 1,500 participants | Interventional | 2004-12-06 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Microfilaria clearance will be assessed in regard to dosage as well as frequency of treatment. Microfilarial clearance is defined by non-detection of microfilaria in the night blood sample. (NCT01213576)
Timeframe: 12 months
| Intervention | participants (Number) |
|---|---|
| Albendazole 400mg and Ivermectin 200mcg/kg Annually | 15 |
| Albendazole 800mg and Ivermectin 400mcg/kg Annually | 14 |
| Albendazole 400mg and Ivermectin 200mcg/kg Biannually | 13 |
| Albendazole 800mg and Ivermectin 400mcg /kg Bi-annually | 17 |
Microfilaria will be detected using the nucleopore filtration technique and analysed according to the respective treatment arms at the 24 month time point. Microfilarial clearance will be defined by non-detection of microfilaria in the night blood sample (NCT01213576)
Timeframe: 24 months
| Intervention | participants (Number) |
|---|---|
| Albendazole 400mg and Ivermectin 200mcg/kg Annually | 17 |
| Albendazole 800mg and Ivermectin 400mcg/kg Annually | 17 |
| Albendazole 400mg and Ivermectin 200mcg/kg Biannually | 14 |
| Albendazole 800mg and Ivermectin 400mcg /kg Bi-annually | 17 |
The effectiveness of three treatment regimens for killing adult female O. volvulus worms based on the percentage of all adult female worms in nodules that are alive 18 months after treatment. (NCT04188301)
Timeframe: 18 months following treatment
| Intervention | Female worms in nodule (Count of Units) |
|---|---|
| IVM + ALB | 127 |
| IDA x 1 Dose | 142 |
| IDA x 3 Doses | 159 |
The effect of three treatment regimens for killing adult female O. volvulus worms will be compared based on the percentage of all adult female worms in nodules that are alive with embryos in the uterus 18 months after treatment. (NCT04188301)
Timeframe: 18 months following treatment.
| Intervention | Female worms in nodules (Count of Units) |
|---|---|
| IVM + ALB | 127 |
| IDA x 1 Dose | 142 |
| IDA x 3 Doses | 159 |
The effect of three treatment regimens for sterilizing adult female O. volvulus worms will be compared based on the percentage of all adult female worms that are fertile in the nodules 18 months after treatment. (NCT04188301)
Timeframe: 18 months following treatment.
| Intervention | Female worms with intact uterus (Count of Units) |
|---|---|
| IVM + ALB | 41 |
| IDA x 1 Dose | 40 |
| IDA x 3 Doses | 34 |
Rates of ocular adverse events of any grade within 3 months will be compared by treatment group. (NCT04188301)
Timeframe: within 3 months of treatment with IDA
| Intervention | Participants (Count of Participants) |
|---|---|
| IVM + ALB | 4 |
| IDA x 1 Dose | 4 |
| IDA x 3 Doses | 3 |
Rates of adverse events grade 3 or higher that occur within 7 days of treatment in the subset of participants who have intraocular microfilariae just prior to treatment with IDA will be compared by treatment group. (NCT04188301)
Timeframe: within 7 days following end of treatment
| Intervention | Participants (Count of Participants) |
|---|---|
| IVM + ALB | 0 |
| IDA x 1 Dose | 0 |
| IDA x 3 Doses | 0 |
Rates of severe adverse events (grade 3 or higher) following 1-day or 3-day triple drug treatment will be compared against those of the comparator regimen of 1 day of IVM/ALB. (NCT04188301)
Timeframe: Within 7 days following end of treatment
| Intervention | Participants (Count of Participants) |
|---|---|
| IVM + ALB | 0 |
| IDA x 1 Dose | 0 |
| IDA x 3 Doses | 0 |
The effectiveness of three treatment regimens for preventing reappearance of microfilariae in the skin as determined by skin snips at 12 and 18 months after treatment will be compared by treatment arm. Measured by the presence of microfilariae in skin snips. (NCT04188301)
Timeframe: Baseline, 12 months, and 18 months following treatment
| Intervention | Count of microfilarae+ participants (Number) | ||
|---|---|---|---|
| Baseline | Month 12 | Month 18 | |
| IDA x 1 Dose | 6 | 21 | 15 |
| IDA x 3 Doses | 0 | 21 | 17 |
| IVM + ALB | 7 | 23 | 20 |
The effectiveness of three treatment regimens for complete clearance of microfilariae from the skin as determined by skin snips at 3, 12, and 18 months after treatment with IDA will be compared by treatment arm. (NCT04188301)
Timeframe: Baseline, 3 months, 12 months, & 18 months following treatment.
| Intervention | Count of Skin Microfilaria (Geometric Mean) | |||
|---|---|---|---|---|
| Baseline | Month 3 | Month 12 | Month 18 | |
| IDA x 1 Dose | 1.7 | 3 | 2.5 | 9.0 |
| IDA x 3 Doses | NA | 2.1 | 4.7 | 8.6 |
| IVM + ALB | 3.1 | 1.9 | 4.9 | 7.0 |
1 review available for albendazole and Parasitemia
| Article | Year |
|---|---|
[Disseminated cysticercosis: report of three cases in Togo].
Topics: Albendazole; Animals; Anthelmintics; Anticonvulsants; Betamethasone; Cysticercosis; Epilepsy; Eye In | 2015 |
11 trials available for albendazole and Parasitemia
| Article | Year |
|---|---|
The effect of three-monthly albendazole treatment on malarial parasitemia and allergy: a household-based cluster-randomized, double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Albendazole; Anthelmintics; Child; Child, Preschool; Double-Blind Method; Drug Ad | 2013 |
Randomised controlled clinical trial of increased dose and frequency of albendazole and ivermectin on Wuchereria bancrofti microfilarial clearance in northern Malawi.
Topics: Adult; Albendazole; Animals; Drug Therapy, Combination; Endemic Diseases; Female; Filariasis; Follow | 2015 |
Effect of Repeated Anthelminthic Treatment on Malaria in School Children in Kenya: A Randomized, Open-Label, Equivalence Trial.
Topics: Adolescent; Albendazole; Anthelmintics; Child; Drug Administration Schedule; Female; Helminthiasis; | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.
Topics: Adult; Albendazole; Animals; Diethylcarbamazine; Drug-Related Side Effects and Adverse Reactions; El | 2016 |
Use of high-dose, twice-yearly albendazole and ivermectin to suppress Wuchereria bancrofti microfilarial levels.
Topics: Adolescent; Adult; Aged; Albendazole; Animals; Drug Therapy, Combination; Endemic Diseases; Female; | 2010 |
Effects of a 3-day regimen of albendazole (800 mg daily) on Loa loa microfilaraemia.
Topics: Adolescent; Adult; Aged; Albendazole; Animals; Cameroon; Child; Drug Administration Schedule; Female | 2002 |
Concomitant parasitism: bancroftian filariasis and intestinal helminths and response to albendazole.
Topics: Adolescent; Adult; Albendazole; Animals; Ascariasis; Ascaris; Elephantiasis, Filarial; Female; Filar | 2005 |
Randomised placebo-controlled comparison of ivermectin and albendazole alone and in combination for Wuchereria bancrofti microfilaraemia in Haitian children.
Topics: Albendazole; Animals; Child; Child, Preschool; Drug Therapy, Combination; Female; Filariasis; Filari | 1997 |
Randomised placebo-controlled comparison of ivermectin and albendazole alone and in combination for Wuchereria bancrofti microfilaraemia in Haitian children.
Topics: Albendazole; Animals; Child; Child, Preschool; Drug Therapy, Combination; Female; Filariasis; Filari | 1997 |
Randomised placebo-controlled comparison of ivermectin and albendazole alone and in combination for Wuchereria bancrofti microfilaraemia in Haitian children.
Topics: Albendazole; Animals; Child; Child, Preschool; Drug Therapy, Combination; Female; Filariasis; Filari | 1997 |
Randomised placebo-controlled comparison of ivermectin and albendazole alone and in combination for Wuchereria bancrofti microfilaraemia in Haitian children.
Topics: Albendazole; Animals; Child; Child, Preschool; Drug Therapy, Combination; Female; Filariasis; Filari | 1997 |
Treatment of the microfilaraemia of asymptomatic brugian filariasis with single doses of ivermectin, diethylcarbamazine or albendazole, in various combinations.
Topics: Adolescent; Adult; Aged; Albendazole; Animals; Brugia malayi; Diethylcarbamazine; Drug Administratio | 1999 |
Two-year follow-up of the microfilaraemia of asymptomatic brugian filariasis, after treatment with two, annual, single doses of ivermectin, diethylcarbamazine and albendazole, in various combinations.
Topics: Adolescent; Adult; Aged; Albendazole; Animals; Brugia malayi; Diethylcarbamazine; Drug Administratio | 2000 |
Effect of a single dose (600 mg) of albendazole on Loa loa microfilaraemia.
Topics: Adolescent; Adult; Albendazole; Animals; Child; Dietary Fats; Female; Filaricides; Humans; Loa; Loia | 2002 |
10 other studies available for albendazole and Parasitemia
| Article | Year |
|---|---|
Orally bioavailable 6-chloro-7-methoxy-4(1H)-quinolones efficacious against multiple stages of Plasmodium.
Topics: Animals; Antimalarials; Humans; Inhibitory Concentration 50; Malaria; Mice; Microsomes, Liver; Paras | 2014 |
Effect of hookworm infection and anthelmintic treatment on naturally acquired antibody responses against the GMZ2 malaria vaccine candidate and constituent antigens.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albendazole; Anthelmintics; Antibodies, Protozoan; Antig | 2021 |
The prevalence of lymphatic filariasis infection and disease following six rounds of mass drug administration in Mandalay Region, Myanmar.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albendazole; Animals; Child; Child, Preschool; Cross-Sec | 2018 |
[Lymphatic filariasis transmission assessment survey in schools three years after stopping mass drug treatment with albendazole and ivermectin in the 7 endemic districts in Togo].
Topics: Albendazole; Animals; Anthelmintics; Antigens, Helminth; Child; Chromatography, Affinity; Cross-Sect | 2015 |
Invasive toxocariasis with hepatic lesions.
Topics: Albendazole; Animals; Anthelmintics; Early Diagnosis; Eosinophilia; Hepatitis; Humans; Male; Middle | 2017 |
[Loa loa meningoencephalitis secondary to treatment with mebendazol].
Topics: Adolescent; Albendazole; Animals; Anthelmintics; Brain Damage, Chronic; Central Nervous System Helmi | 2011 |
Higher-dose, more frequent treatment of Wuchereria bancrofti.
Topics: Albendazole; Animals; Drug Therapy, Combination; Filariasis; Filaricides; Humans; Ivermectin; Parasi | 2010 |
Infestation of tracer lambs by Fasciola hepatica in Tunisia: determining periods for strategic anthelmintic treatments.
Topics: Albendazole; Analysis of Variance; Anemia; Animals; Anthelmintics; Cohort Studies; Fasciola hepatica | 2011 |
Long-term benzimidazole treatment of alveolar echinococcosis with hematogenic subcutaneous and bone dissemination.
Topics: Albendazole; Anticestodal Agents; Benzimidazoles; Bone Diseases, Infectious; Diagnosis, Differential | 2003 |
[Patient from the Republic of Congo with intermittent ocular pain].
Topics: Adult; Albendazole; Animals; Anthelmintics; Congo; Conjunctiva; Conjunctival Diseases; Humans; Loa; | 2007 |